# US 2025/0084171 A1 · Methods for treating myositis using fcrn antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084171 A1
- Document ID: US20250084171A1
- Status: Published application
- Kind: A1
- Application number: 18/810,851
- Filed: 2024-08-21
- Published: 2025-03-13
- Earliest claimed: 2022-02-21
- Assignees: argenx BV
- Applicants: argenx BV
- Inventors: Sebastian Paul van der Woning; Olivier Boyer; Laurent Drouot
- Web page: https://patentgrep.com/patent/US20250084171A1

## CPC

- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- G01N 33/6854: {Immunoglobulins}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods of treating myositis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of myositis and for use in the manufacture of a medicament for the treatment of myositis are also provided herein.

## Claims

### Claim 1

A method of treating myositis in a subject in need thereof, the method comprising administering to the subject an effective amount of a human neonatal Fc receptor (FcRn) antagonist, wherein the FcRn antagonist comprises or consists of a variant Fc region or FcRn binding fragment thereof.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the FcRn antagonist comprises or consists of a variant Fc region, wherein the variant Fc region comprises or consists of a first Fc domain and a second Fc domain which form a homodimer or heterodimer, and wherein the first Fc domain and/or the second Fc domain comprise amino acids Y, T, E, K, and F at EU positions 252, 254, 256, 433, and 434, respectively.

### Claim 7

(canceled)

### Claim 8 (depends on 6)

The method of claim 6, wherein the first Fc domain and/or the second Fc domain comprise amino acids Y, T, E, K, F, and Y at EU positions 252, 254, 256, 433, 434, and 436, respectively.

### Claim 9 (depends on 6)

The method of claim 6, wherein the first Fc domain and/or the second Fc domain comprise an amino acid sequence independently selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the FcRn antagonist is efgartigimod.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the FcRn antagonist is administered subcutaneously to the subject at a fixed dose of 20 mg to 20,000 mg once weekly, once every two weeks, once every three weeks, once every four weeks, once monthly, or once every six weeks: or wherein the FcRn antagonist is administered intravenously at a dose of 0.2 mg/kg to 200 mg/kg once weekly or once every two weeks.

### Claim at position 11

14-16. (canceled)

### Claim 17 (depends on 13)

The method of claim 13, wherein the FcRn antagonist is first administered subcutaneously at a fixed dose of about 1000 mg twice on the same day.

### Claim 18

(canceled)

### Claim 19 (depends on 11)

The method of claim 11, wherein the efgartigimod is administered subcutaneously at a fixed dose of about 1000 mg once weekly.

### Claim 20 (depends on 11)

The method of claim 11, wherein the efgartigimod is administered subcutaneously at a fixed dose of 1000 mg once weekly.

### Claim 21 (depends on 1)

The method of claim 1, wherein the FcRn antagonist is co-formulated with hyaluronidase and administered subcutaneously.

### Claim at position 17

22-26. (canceled)

### Claim 27 (depends on 13)

The method of claim 13, wherein the FcRn antagonist is administered intravenously at a dose of 10 mg/kg or 25 mg/kg once weekly or once every two weeks.

### Claim at position 19

28-30. (canceled)

### Claim 31 (depends on 1)

The method of claim 1, wherein the FcRn antagonist is administered for at least 24 weeks or for at least 52 weeks.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The method of claim 1, further comprising administering to the subject a dose of corticosteroid.

### Claim at position 23

34-39. (canceled)

### Claim 40 (depends on 1)

The method of claim 1, wherein the myositis is selected from the group consisting of immune-mediated necrotizing myopathy (IMNM), dermatomyositis (DM), juvenile dermatomyositis (JDM), polymyositis (PM), and antisynthetase syndrome (ASyS).

### Claim at position 25

41-44. (canceled)

### Claim 45 (depends on 1)

The method of claim 1, wherein the subject has an active DM skin rash.

### Claim at position 27

46-47. (canceled)

### Claim 48 (depends on 1)

The method of claim 1, wherein the subject has a detectable serum level of a myositis-associated antibody (MAA) or a myositis-specific antibody (MSA).

### Claim 49 (depends on 48)

The method of claim 48, wherein:
the MSA is an anti-aminoacyl-tRNA synthetase antibody, wherein the anti-aminoacyl-tRNA synthetase antibody is selected from the group consisting of anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, and anti-OJ antibodies: or
the MSA is selected from the group consisting of anti-SRP, anti-HMGCR, anti-Mi-2, anti-TIF1, anti-SAE, anti-NXP, and anti-MDA5 antibodies: or
the MAA is selected from the group consisting of anti-PM/Scl 75, anti-Ku, anti-snRNP, anti-Ro52 (SSA), anti-Ro/60 (SSA), and anti-La (SSB) antibodies.

### Claim at position 30

50-52. (canceled)

### Claim 53 (depends on 48)

The method of claim 48, wherein the subject shows a reduction in serum level of the MAA or MSA following administration of the anti-FcRn antagonist.

### Claim at position 32

54-55. (canceled)

### Claim 56 (depends on 1)

The method of claim 1, wherein the subject shows at least a 20 point total improvement score (TIS) after administration of the FcRn antagonist.

### Claim at position 34

57-60. (canceled)

### Claim 61 (depends on 1)

The method of claim 1, wherein the subject shows at least a 20% improvement in manual muscle testing-8 (MMT8) score after administration of the FcRn antagonist.

### Claim 62

(canceled)

### Claim 63 (depends on 1)

The method of claim 1, wherein the subject shows at least a 20% decrease in patient's global assessment of disease activity (PGA) after administration of the FcRn antagonist.

### Claim 64

(canceled)

### Claim 65 (depends on 1)

The method of claim 1, further comprising measuring at least one muscle-associated enzyme in the subject, wherein a reduction in the at least one muscle-associated enzyme in the subject is indicative of disease improvement.

### Claim at position 40

66-70. (canceled)

### Claim 71

A method of treating myositis in a subject that has received a first FcRn antagonist and is receiving a corticosteroid dosing regimen, the method comprising:
a) administering to the subject an effective amount of a second FcRn antagonist;
b) measuring in vitro a serum level of an MAA or an MSA in a blood sample taken from the subject; and
c) comparing the serum level of the MAA or the MSA to a reference value associated with myositis in the subject,
wherein the corticosteroid dosing regimen is maintained if the serum level of the MAA or the MSA in the sample is greater than or equal to the reference value, or wherein the corticosteroid dosing regimen is tapered if the serum level of the MAA or the MSA is less than the reference value.

### Claim 72

A method for treating myositis in a subject comprising:
(a) administering to the subject one or more initial doses of an effective amount of a first FcRn antagonist,
(b) administering to the subject one or more further doses of an effective amount of a second FcRn antagonist if the serum level of an MAA or an MSA in the subject after step (a) is greater than or equal to a reference value associated with myositis in the subject, or discontinuing treatment with the first FcRn antagonist if the serum level of the MAA or the MSA in the subject after step (a) is less than a reference value associated with active disease in the subject.

### Claim 73

A method for treating myositis in a subject, the method comprising: administering to the subject an effective amount of a second FcRn antagonist,
wherein the myositis has relapsed in the subject following prior therapy with a first FcRn antagonist and wherein the subject has a serum level of an MAA or an MSA that is greater than or equal to a reference value associated with myositis in the subject.

### Claim at position 44

74-102. (canceled)
